Few small-cap life-science stories are as double-edged as Allergy Therapeutics. On the science, the Worthing-based specialist enters mid-2026 with the most tangible clinical validation in its history — a German regulatory approval for its short-course grass pollen injection. On the balance sheet, it's a company reshaped by distress: recapitalised, heavily indebted, and majority-owned by a private investor after a mandatory cash offer priced at a single penny per share.
The Quick Version
- Grassmuno (Grass MATA MPL) received German marketing authorisation from the Paul Ehrlich Institut in December 2025, launching in Germany in Q1 2026 via subsidiary Bencard Allergie.
- The pivotal adult Phase III G306 trial met its primary endpoint in November 2023, later published in the journal Allergy; a paediatric Phase III (G308) began screening in October 2025.
- For the year to 30 June 2025, revenue was broadly flat at £55.0m, with a £40.1m net loss and £12.8m of cash against long-term borrowings of about £53.0m.
- After a 2023-2025 recapitalisation, ZQ Capital (via SkyGem) became the controlling shareholder following a lapsed 1p-per-share mandatory offer; Southern Fox holds a large minority.
- The company is exploring a dual primary listing on the Hong Kong Stock Exchange and a potential equity raise.
What Allergy Therapeutics Actually Does
Founded in 1998 and headquartered on the English south coast, Allergy Therapeutics develops and sells allergen immunotherapy — treatments seeking to modify the underlying allergic response rather than just suppress symptoms. It markets across continental Europe, principally through German commercial arm Bencard Allergie. The business splits into an established, revenue-generating European product portfolio and a research pipeline for short-course grass pollen and peanut allergy therapies. Shares trade on AIM under AGY.
The Science: Short Courses Over Long Ones
Conventional subcutaneous immunotherapy typically requires many injections over three years or more. Allergy Therapeutics' lead products combine allergoids adsorbed onto a proprietary microcrystalline tyrosine depot with a monophosphoryl lipid A adjuvant, aiming for a pre-seasonal course of only around six injections — free of aluminium salts, a point of differentiation given growing scrutiny of aluminium adjuvants. For peanut allergy, the company pursues a virus-like particle approach designed to desensitise patients through a short course.
The Grassmuno Approval, Explained
In December 2025 the Paul Ehrlich Institut, Germany's federal vaccines and biomedicines authority, granted marketing authorisation for Grassmuno under the country's TAV framework, which holds allergy immunotherapies to the same evidential standard as other prescription medicines. Management called Grassmuno the first subcutaneous grass pollen immunotherapy approved through that route, launching in Germany in Q1 2026 via Bencard Allergie. The pivotal G306 trial met its endpoint in November 2023 and was subsequently published in the peer-reviewed journal Allergy.
A second Phase III trial, G308, testing the same approach in children, began screening in October 2025. The peanut programme's Phase I/IIa PROTECT study showed dose-dependent reductions in skin reactivity — early findings, not proof of efficacy.
The Financial Reality: Recapitalised and Leveraged
For the year to 30 June 2025, revenue was £55.0m, broadly flat. The operating loss narrowed to £28.2m from £35.3m, while the net loss widened slightly to £40.1m from £38.6m. Cash stood at £12.8m against long-term borrowings of roughly £53.0m. The funding architecture has been rebuilt repeatedly — a ~£41m ZQ Capital facility in 2023, a ~£40.8m equity raise in 2024, and warrant exercises in late October 2025 that repaid a £50m shareholder facility in full, followed by a new £50m unsecured, uncommitted shareholder facility (committed availability around £40m).
Who's Actually In Control
ZQ Capital Management, via SkyGem Acquisition, became the controlling shareholder following the recapitalisation, crossing the UK Takeover Code's 30% threshold and triggering a mandatory cash offer in early 2025 at 1p per share — valuing the entire equity at around £47.9m. A second large holder, Southern Fox, gave an irrevocable undertaking not to accept, making any squeeze-out impossible, and the offer lapsed. The result is a listed company with a dominant majority owner, a substantial second shareholder and a thin free float.
Risks Worth Weighing
The company remains loss-making and dependent on shareholder funding described as uncommitted; any withdrawal would be serious. Leverage is high relative to revenue, and the going-concern assessment rests on forecasts and continued facility access. Commercial execution on Grassmuno is unproven, and German approval doesn't guarantee pan-European reach or reimbursement. The concentrated share register limits free-float liquidity and can leave minority holders exposed to decisions taken in the interests of the majority owner.
What to Watch Next
A successful Grassmuno launch in Germany during 2026, with early prescription-uptake evidence. Further European marketing authorisations for Grass MATA MPL. A read-out from the paediatric G308 study. Any formalised Hong Kong dual listing, equity raise, or refinancing that reduces reliance on uncommitted shareholder facilities.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...